Table 2 General characteristics of the T2DM in postmenopausal women according to HbA1c more or lower than 8.5%
HbA1c < 8.5% | HbA1c ≥ 8.5% | P value | |
|---|---|---|---|
N | 103 | 134 | |
Age(years) | 65.38 ± 9.36 | 63.67 ± 9.09 | 0.158 |
Menopause’s years(years) | 14.32 ± 9.37 | 13.34 ± 9.71 | 0.436 |
Diabetic duration(years) | 12.44 ± 8.20 | 11.81 ± 8.98 | 0.583 |
BMI(Kg/m2) | 24.54 ± 3.74 | 24.21 ± 4.16 | 0.525 |
eGFR(mL/min/1. 73m2) | 81.43 ± 24.98 | 92.40 ± 21.45 | 0.001 |
creatinine(μmol/L) | 77.21 ± 43.50 | 63.02 ± 22.33 | 0.001 |
UA(mg/dL) | 301.52 ± 96.58 | 278.51 ± 103.94 | 0.083 |
TC(mmol/L) | 4.52 (3.84–5.16) | 4.55 (3.76–5.41) | 0.666 |
TG(mmol/L) | 1.36 (1.02–1.82) | 1.65 (1.10–2.42) | 0.013 |
HDL-c(mmol/L) | 1.22 (1.05–1.47) | 1.11 (0.92–1.33) | 0.007 |
LDL-c(mmol/L) | 2.68 (2.04–3.19) | 2.63 (1.98–3.42) | 0.792 |
N-MID osteocalcin(ng/ml) | 19.84 ± 10.71 | 15.56 ± 8.01 | < 0.001 |
PINP(ng/ml) | 51.71 ± 29.88 | 45.97 ± 24.90 | 0.153 |
β-CTX(ng/ml) | 0.61 ± 0.31 | 0.53 ± 0.26 | 0.062 |
PTH(pg/ml) | 49.09 ± 37.89 | 39.08 ± 21.38 | 0.021 |
25(OH)D3(ng/ml) | 10.94 ± 6.92 | 11.44 ± 6.78 | 0.492 |
History of fracture,n (%) | 6 (5.83%) | 11 (8.21%) | 0.614 |
Microvascular complications, n (%) | 78 (75.73%) | 105 (78.36%) | 0.632 |
Macrovascular complications, n (%) | 63 (61.17%) | 81 (60.45%) | 0.911 |
Treatment | |||
Insulin,n(%) | 27 (26.21%) | 36 (26.87%) | 0.901 |
Oral anti-diabetic agents,n(%) | 9 (8.74%) | 14 (10.45%) | |
Insulin+Oral anti-diabetic agents, n(%) | 67 (65.05%) | 84 (62.69%) | |
Use of statin medication | 37 (35.92%) | 75 (55.97%) | 0.002 |